Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

被引：58

作者：

Ranganathan, P

Eisen, S

Yokoyama, WM

McLeod, HL

机构：

[1] Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[3] VA Med Ctr, St Louis, MO 63106 USA

[4] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[6] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA

[7] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷 / 01期

关键词：

D O I：

10.1136/ard.62.1.4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA.

引用

页码：4 / 9

页数：6

共 77 条

[1] METHOTREXATE IN RHEUMATOID-ARTHRITIS - TOXIC EFFECTS AS THE MAJOR FACTOR IN LIMITING LONG-TERM TREATMENT [J].